- Report
- November 2023
- 87 Pages
North America
From €3095EUR$3,450USD£2,646GBP
- Report
- May 2025
- 138 Pages
Global
From €4351EUR$4,850USD£3,719GBP
- Report
- August 2025
- 150 Pages
Global
From €4351EUR$4,850USD£3,719GBP
- Clinical Trials
- February 2025
- 604 Pages
Global
From €3095EUR$3,450USD£2,646GBP
- Clinical Trials
- November 2024
- 893 Pages
Global
From €3095EUR$3,450USD£2,646GBP
- Report
- October 2023
- 689 Pages
Global
From €8966EUR$9,995USD£7,665GBP
- Report
- July 2020
- 81 Pages
Global
From €4037EUR$4,500USD£3,451GBP
- Report
- August 2023
- 99 Pages
Global
From €3500EUR$4,180USD£3,097GBP
- Report
- January 2025
- 132 Pages
Global
From €852EUR$950USD£729GBP

Macular Edema is a condition in which fluid accumulates in the macula, the central part of the retina responsible for sharp, central vision. It is a common complication of diabetes, and can also be caused by other diseases or conditions such as uveitis, retinal vein occlusion, and retinopathy of prematurity. Treatment options for macular edema include laser photocoagulation, intravitreal injections, and vitrectomy.
Optical treatments for macular edema include laser photocoagulation, which uses a laser to reduce the amount of fluid in the macula. Intravitreal injections are also used to reduce fluid accumulation, and vitrectomy is a surgical procedure that removes the vitreous gel from the eye and replaces it with a gas bubble.
Companies in the macular edema market include Regeneron Pharmaceuticals, Allergan, Novartis, Roche, and Bayer. Show Less Read more